Abstract
Primary immune thrombocytopenia (ITP) is an autoimmune disease leading to a decreased platelet count and an ensuing haemorrhagic risk. First-line treatment against ITP consists in the administration of immunomodulators aimed at decreasing platelet destruction. Up to 70% of individuals with an ITP diagnosis treated with corticosteroids do not achieve a clinical response or demonstrate a high relapse rate, requiring treatment to prevent a haemorrhagic risk. Less than 30% of patients treated with thrombopoietin analogues, 60% of those treated with splenectomy and 20% of those treated with rituximab reach sustained remission in the absence of treatment. Because of these reasons, it is unquestionable that treatment of patients with ITP should be optimized. Through this study, we will review new actual and future options of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
